{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:20Z","timestamp":1787955980024,"version":"build-2784847793"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.oftal.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T22:21:11Z","timestamp":1521843671000},"page":"458-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Uve\u00edtis y desprendimiento seroso de retina secundarios al tratamiento sist\u00e9mico con dabrafenib y trametinib"],"prefix":"10.1016","volume":"93","author":[{"given":"T.","family":"Rueda-Rueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"S\u00e1nchez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moruno-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Molina-Socola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Mart\u00ednez-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"L\u00f3pez-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftal.2018.01.008_bib0055","article-title":"Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma","volume":"5","author":"Homet-Moreno","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.oftal.2018.01.008_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11912-016-0554-5","article-title":"Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era","volume":"18","author":"Wood","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.oftal.2018.01.008_bib0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.oftal.2018.01.008_bib0070","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftal.2018.01.008_bib0075","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.oftal.2018.01.008_bib0080","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oftal.2018.01.008_bib0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-015-0049-9","article-title":"Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib","volume":"5","author":"Draganova","year":"2015","journal-title":"J Ophthalmic Inflamm Infec"},{"key":"10.1016\/j.oftal.2018.01.008_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000357060","article-title":"Uveitis as a Result of MAP Kinase Pathway Inhibition","volume":"4","author":"Joshi","year":"2013","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.oftal.2018.01.008_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2016.1246666","article-title":"Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report","author":"Lim","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oftal.2018.01.008_bib0100","first-page":"1","article-title":"Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report","author":"Niro","year":"2016","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036566911830039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036566911830039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T16:27:32Z","timestamp":1535473652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036566911830039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S036566911830039X"],"URL":"https:\/\/doi.org\/10.1016\/j.oftal.2018.01.008","relation":{},"ISSN":["0365-6691"],"issn-type":[{"value":"0365-6691","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uve\u00edtis y desprendimiento seroso de retina secundarios al tratamiento sist\u00e9mico con dabrafenib y trametinib","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}